Alvotech (ALVO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alvotech has reported a significant increase in preliminary revenues and EBITDA for Q2 2024, with a 10-fold year-over-year revenue surge for the first half of the year and a strong growth in product sales. The company expects record operating performance with a positive adjusted EBITDA, marking a turnaround from the previous year’s losses. These financial achievements are attributed to successful global product launches and clinical milestones.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.